



Clinical trial results:

A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids

Summary

EudraCT number	2018-000452-18
Trial protocol	AT GR ES GB IT
Global end of trial date	03 October 2022

Results information

Result version number	v1
This version publication date	13 October 2023
First version publication date	13 October 2023

Trial information

Trial identification

Sponsor protocol code	CETB115J2411
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03524612
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 October 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 October 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to assess ability of eltrombopag to induce sustained response off treatment by Month 12 in Immune Thrombocytopenia (ITP) patients who relapsed or failed to respond to first-line steroid treatment.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 4
Country: Number of subjects enrolled	Brazil: 6
Country: Number of subjects enrolled	Chile: 11
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Greece: 8
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Japan: 2
Country: Number of subjects enrolled	Mexico: 3
Country: Number of subjects enrolled	Oman: 4
Country: Number of subjects enrolled	Russian Federation: 9
Country: Number of subjects enrolled	Spain: 21
Country: Number of subjects enrolled	Switzerland: 2
Country: Number of subjects enrolled	Turkey: 12
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	United States: 3
Worldwide total number of subjects	105
EEA total number of subjects	50

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	78
From 65 to 84 years	24
85 years and over	3

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was conducted in 32 investigative sites in 15 countries: 1 (Austria), 3 (Brazil), 2 (Chile), 2 (France), 2 (Greece), 2 (Italy), 1 (Japan), 2 (Mexico), 1 (Oman), 2 (Russia), 7 (Spain), 1 (Switzerland), 3 (Turkey), 1 (UK), 2 (USA).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Eltrombopag
------------------	-------------

Arm description:

Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of $\geq 100 \times 10^9/L$ (CR), after 1st line steroids had failed.

Arm type	Tablet for oral use
Investigational medicinal product name	Eltrombopag
Investigational medicinal product code	
Other name	ETB115
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

12.5, 25, 50 and 75 mg tablets for oral use once daily

Number of subjects in period 1	Eltrombopag
Started	105
Completed	63
Not completed	42
Adverse event, serious fatal	3
Consent withdrawn by subject	7
Adverse event, non-fatal	10
Physician Decision (Patient non-compliant)	1
Patient Decision (Patient Changed Her Address)	1
Lost to follow-up	2
Patient Decision (Personal Reasons)	1
New therapy for study indication	6
Lack of efficacy	10
Protocol deviation	1

Baseline characteristics

Reporting groups

Reporting group title	Eltrombopag
-----------------------	-------------

Reporting group description:

Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of $\geq 100 \times 10^9/L$ (CR), after 1st line steroids had failed.

Reporting group values	Eltrombopag	Total	
Number of subjects	105	105	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	78	78	
From 65-84 years	24	24	
85 years and over	3	3	
Age Continuous			
Units: Years			
arithmetic mean	48.1		
standard deviation	± 19.39	-	
Sex: Female, Male			
Units: Participants			
Female	64	64	
Male	41	41	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	5	5	
Asian	2	2	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	2	2	
White	95	95	
More than one race	0	0	
Unknown or Not Reported	1	1	
Time since initial diagnosis			
Time since initial diagnosis is the difference in days between the date of initial diagnosis and the date of first dose of eltrombopag.			
Units: Days			
arithmetic mean	366.37		
standard deviation	± 911.420	-	

End points

End points reporting groups

Reporting group title	Eltrombopag
Reporting group description: Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of $\geq 100 \times 10^9/L$ (CR), after 1st line steroids had failed.	

Primary: Percentage of participants with sustained response off treatment (SRoT) by 12 months

End point title	Percentage of participants with sustained response off treatment (SRoT) by 12 months ^[1]
End point description: Sustained response off treatment (SRoT) was defined as: reaching platelet count $\geq 100 \times 10^9/L$ (complete response [CR]) and then maintaining platelet counts around $100 \times 10^9/L$ for 2 months (no counts below $70 \times 10^9/L$), AND then tapering off the drug until treatment discontinuation while maintaining platelet count $\geq 30 \times 10^9/L$ in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.	
End point type	Primary
End point timeframe: Month 12	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to EudraCT system limitations, there must be at least two comparison groups selected for the statistical analysis to be entered in the EudraCT system.	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Percentage of participants				
number (confidence interval 95%)	30.5 (21.9 to 40.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median duration of sustained response off treatment (SRoT) after treatment discontinuation for participants with sustained response off treatment

End point title	Median duration of sustained response off treatment (SRoT) after treatment discontinuation for participants with sustained response off treatment
End point description: Sustained response off treatment (SRoT) was defined as: reaching platelet count $\geq 100 \times 10^9/L$ (complete response [CR]) and then maintaining platelet counts around $100 \times 10^9/L$ for 2 months (no counts below $70 \times 10^9/L$), AND then tapering off the drug until treatment discontinuation while maintaining platelet count $\geq 30 \times 10^9/L$ in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.	
End point type	Secondary

End point timeframe:

From last dose of eltrombopag to month 12

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Weeks				
median (full range (min-max))	33.3 (4 to 51)			

Statistical analyses

No statistical analyses for this end point

Secondary: Estimated median duration of sustained response off treatment (SRoT) for participants with sustained response off treatment at month 12 and who enter 12 months follow-up period

End point title	Estimated median duration of sustained response off treatment (SRoT) for participants with sustained response off treatment at month 12 and who enter 12 months follow-up period
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Sustained response off treatment (SRoT) was defined as: reaching platelet count $\geq 100 \times 10^9/L$ (complete response [CR]) and then maintaining platelet counts around $100 \times 10^9/L$ for 2 months (no counts below $70 \times 10^9/L$), AND then tapering off the drug until treatment discontinuation while maintaining platelet count $\geq 30 \times 10^9/L$ in the absence of bleeding (no bleeding AEs) or use of any rescue therapy.

Patients with SRoT until month 12 who entered follow-up and did not relapse by cut-off date/Month 24 were censored at the earliest of discontinuation date/death date/Month 24 platelet assessment date/cutoff date. Patients with SRoT until Month 12 patients who did not enter or do not yet have data in follow-up phase are censored at their Month 12 platelet assessment date.

End point type	Secondary
----------------	-----------

End point timeframe:

From last dose of eltrombopag to relapse, assessed up to month 24

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[2]			
Units: Weeks				
median (full range (min-max))	(to)			

Notes:

[2] - Not estimable due to number of patients who are censored

Statistical analyses

No statistical analyses for this end point

Secondary: Estimated median duration of sustained response off treatment (SRot) for all patients

End point title	Estimated median duration of sustained response off treatment (SRot) for all patients
-----------------	---------------------------------------------------------------------------------------

End point description:

Patients who tapered and discontinued successfully, or did not relapse/die by cutoff date /month 24 were censored at the earliest of discontinuation date/death date/month 24 platelet assessment date/cutoff date.

End point type	Secondary
----------------	-----------

End point timeframe:

From last dose of eltrombopag to month 24

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[3]			
Units: Weeks				
median (full range (min-max))	(to)			

Notes:

[3] - Not estimable due to number of patients who are censored

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with sustained response off treatment until month 24

End point title	Percentage of participants with sustained response off treatment until month 24
-----------------	---------------------------------------------------------------------------------

End point description:

Sustained response off treatment is defined as reach platelet count $\geq 100 \times 10^9/L$ (complete response [CR]) and then maintain platelet counts around $100 \times 10^9/L$ for 2 months (no counts below $70 \times 10^9/L$) AND then taper off the drug until treatment discontinuation while, maintain platelet count $\geq 30 \times 10^9/L$ in the absence of bleeding (no bleeding AEs) or use of any rescue therapy

End point type	Secondary
----------------	-----------

End point timeframe:

Month 15, 18, 21 and 24

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Participants				
Month 15	21			
Month 18	18			
Month 21	14			
Month 24	15			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with early response within first month

End point title	Percentage of participants with early response within first month
End point description: Early response is defined as reaching a platelet count $\geq 50 \times 10^9/L$ at least once within the first month (month 1) without bleeding events and no rescue therapy.	
End point type	Secondary
End point timeframe: By 1 month	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Percentage of participants				
number (confidence interval 95%)	76.2 (66.9 to 84.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with recovery response in case of loss of response during or after tapering of eltrombopag until month 24

End point title	Percentage of participants with recovery response in case of loss of response during or after tapering of eltrombopag until month 24
End point description: Recovery response is defined as platelet count $\geq 30 \times 10^9/L$ after eltrombopag is re-introduced, in case of loss of response ($< 30 \times 10^9/L$ and/or bleeding event) without bleeding events and no rescue therapy.	
End point type	Secondary
End point timeframe: Up to month 24	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Percentage of participants				
number (confidence interval 95%)				
Participants with loss of response	11.4 (6.0 to 19.1)			
Participants with recovery response	6.7 (2.7 to 13.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Relative change from baseline in platelet count over time

End point title	Relative change from baseline in platelet count over time
End point description:	Relative change (%) is the absolute change divided by the platelet counts at baseline and multiplied by 100.
End point type	Secondary
End point timeframe:	Baseline, month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	104			
Units: Percentage				
arithmetic mean (standard deviation)				
3 Months	1384.29 (± 3383.702)			
6 Months	1313.10 (± 3459.616)			
9 Months	1396.68 (± 3238.680)			
12 Months	1464.95 (± 3509.964)			
15 Months	1622.19 (± 3712.156)			
18 Months	1664.90 (± 3718.191)			
21 Months	2527.20 (± 5098.612)			
24 Months	1691.68 (± 3611.977)			
end of treatment visit	1213.91 (± 2952.719)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who maintain platelet counts level within 12 months and every 3 months until month 24

End point title	Percentage of participants who maintain platelet counts level within 12 months and every 3 months until month 24
-----------------	------------------------------------------------------------------------------------------------------------------

End point description:

Platelet counts level is defined as having platelet counts $\geq 30 \times 10^9/L$ without bleeding events and no rescue therapy.

End point type	Secondary
----------------	-----------

End point timeframe:

From first time of reaching the level to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Percentage of participants				
number (confidence interval 95%)				
Mnt PLT lvl f/1st time of reach. that lvl to mo 3	49.5 (39.6 to 59.5)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 6	38.1 (28.8 to 48.1)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 9	28.6 (20.2 to 38.2)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 12	28.6 (20.2 to 38.2)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 15	20.0 (12.8 to 28.9)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 18	17.1 (10.5 to 25.7)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 21	13.3 (7.5 to 21.4)			
Mnt PLT lvl f/1st time of reach. that lvl to mo 24	14.3 (8.2 to 22.5)			
Mnt PLT lvl f/1st time of reach. that lvl to EOT	31.4 (22.7 to 41.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire

End point title	Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire
-----------------	----------------------------------------------------------------------------------------------------------------

End point description:

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) instrument is a 13-item validated tool used to measure an individual's level of fatigue during usual daily activities over the past 7 days (Cella 2002, Webster 2003). FACIT-Fatigue is a subscale of the FACIT measurement system.

FACIT-fatigue is scored using a 4-point Likert scale (4=not at all fatigued to 0=very much fatigued) where the total possible score ranges from 0-5; higher scores represent better HRQoL.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	5.42 (± 9.700)			
6 Months	6.15 (± 8.779)			
9 Months	6.89 (± 9.291)			
12 Months	7.90 (± 9.064)			
15 Months	7.12 (± 11.720)			
18 Months	8.87 (± 11.644)			
21 Months	8.80 (± 11.112)			
24 Months	8.69 (± 10.635)			
end of treatment visit	5.40 (± 10.116)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th6) questionnaire

End point title	Change from baseline in Functional Assessment of Cancer Therapy- Thrombocytopenia (FACT-Th6) questionnaire
-----------------	------------------------------------------------------------------------------------------------------------

End point description:

FACT-Th6 instrument is used to measure worry/concern about bleeding and bruising, and the impact of this worry/concern on physical and social activity (Cella 2006). FACT-Th6 is a 6-item subset of the more detailed FACT-Th, which is an 18-item subscale of the validated FACT that specifically measures concerns related to thrombocytopenia in the past 7 days. The FACT-Th6 is scored using a 5-level Likert scale (0=not at all to 4=very much) and is calculated by summing scores for the 6-items; therefore, scores can range from 0–24, with higher scores representing better HRQoL

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	3.80 (± 5.130)			
6 Months	4.35 (± 6.312)			
9 Months	5.60 (± 6.114)			
12 Months	5.62 (± 6.505)			
15 Months	5.44 (± 8.949)			
18 Months	7.04 (± 7.654)			
21 Months	7.32 (± 7.351)			
24 Months	7.08 (± 7.048)			
end of treatment visit	4.15 (± 6.631)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Bodily Pain (BP) Score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Bodily Pain (BP) Score
End point description:	SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL
End point type	Secondary
End point timeframe:	Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	7.55 (± 24.199)			
6 Months	2.75 (± 24.636)			
9 Months	3.82 (± 21.507)			
12 Months	7.53 (± 25.547)			
15 Months	1.96 (± 36.697)			

18 Months	13.61 (± 26.662)			
21 Months	3.00 (± 20.967)			
24 Months	9.27 (± 29.090)			
end of treatment visit	5.19 (± 29.460)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: General Health (GH) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: General Health (GH) score
-----------------	--------------------------------------------------------------------------------------------------------

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	4.12 (± 18.894)			
6 Months	5.39 (± 20.646)			
9 Months	7.40 (± 17.990)			
12 Months	7.62 (± 18.420)			
15 Months	11.17 (± 20.470)			
18 Months	14.78 (± 26.801)			
21 Months	14.36 (± 25.541)			
24 Months	13.92 (± 19.577)			
end of treatment visit	3.80 (± 18.122)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Mental Health (MH) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Mental Health (MH) score
-----------------	-------------------------------------------------------------------------------------------------------

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	6.74 (± 15.775)			
6 Months	6.97 (± 18.149)			
9 Months	9.78 (± 15.074)			
12 Months	10.26 (± 16.125)			
15 Months	7.08 (± 22.259)			
18 Months	15.22 (± 22.334)			
21 Months	14.32 (± 20.948)			
24 Months	12.50 (± 17.103)			
end of treatment visit	6.82 (± 17.058)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Physical Functioning (PF) score

End point title Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Physical Functioning (PF) score

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL.

End point type Secondary

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	8.48 (± 23.842)			
6 Months	10.90 (± 26.069)			
9 Months	12.67 (± 28.074)			
12 Months	14.31 (± 28.767)			
15 Months	11.87 (± 37.469)			
18 Months	19.35 (± 33.449)			
21 Months	24.09 (± 31.983)			
24 Months	16.54 (± 35.882)			
end of treatment visit	9.00 (± 29.376)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Role Emotional (RE) score

End point title Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Role Emotional (RE) score

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health,

Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL

End point type	Secondary
End point timeframe:	
Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	4.42 (± 22.371)			
6 Months	6.15 (± 23.270)			
9 Months	8.89 (± 22.361)			
12 Months	10.20 (± 23.260)			
15 Months	4.86 (± 27.022)			
18 Months	13.04 (± 26.211)			
21 Months	16.29 (± 25.520)			
24 Months	16.03 (± 20.128)			
end of treatment visit	7.25 (± 22.078)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Role Physical (RP) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Role Physical (RP) score
End point description:	
SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL	
End point type	Secondary
End point timeframe:	
Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	13.26 (± 22.958)			
6 Months	9.43 (± 27.066)			
9 Months	17.36 (± 24.165)			
12 Months	19.94 (± 29.232)			
15 Months	15.89 (± 37.454)			
18 Months	22.55 (± 32.680)			
21 Months	27.27 (± 33.604)			
24 Months	29.81 (± 32.849)			
end of treatment visit	15.88 (± 33.332)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Social Functioning (SF) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Social Functioning (SF) score
-----------------	------------------------------------------------------------------------------------------------------------

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	6.06 (± 24.143)			
6 Months	7.17 (± 26.951)			
9 Months	10.00 (± 22.863)			
12 Months	16.38 (± 26.408)			
15 Months	14.58 (± 30.986)			
18 Months	26.63 (± 24.514)			
21 Months	20.45 (± 26.318)			
24 Months	25.96 (± 22.617)			
end of treatment visit	11.18 (± 26.236)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Vitality (VT) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Vitality (VT) score
End point description:	SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL
End point type	Secondary
End point timeframe:	Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	7.48 (± 18.418)			
6 Months	6.45 (± 20.696)			

9 Months	12.78 (± 20.982)			
12 Months	14.33 (± 22.398)			
15 Months	8.33 (± 26.237)			
18 Months	12.23 (± 27.918)			
21 Months	17.33 (± 26.087)			
24 Months	11.06 (± 24.705)			
end of treatment visit	8.97 (± 22.503)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Physical Component Summary (PCS) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Physical Component Summary (PCS) score
-----------------	---------------------------------------------------------------------------------------------------------------------

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	3.46 (± 7.445)			
6 Months	2.72 (± 8.165)			
9 Months	3.92 (± 7.608)			
12 Months	4.85 (± 8.946)			
15 Months	4.37 (± 11.754)			
18 Months	6.77 (± 9.950)			
21 Months	6.65 (± 8.017)			
24 Months	6.63 (± 9.627)			
end of treatment visit	3.30 (± 9.728)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Mental Component Summary (MCS) score

End point title	Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire: Mental Component Summary (MCS) score
-----------------	-------------------------------------------------------------------------------------------------------------------

End point description:

SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to month 3, 6, 9, 12, 15, 18, 21 and 24 and end of treatment visit

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	85			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
3 Months	2.34 (± 8.443)			
6 Months	2.85 (± 9.451)			
9 Months	4.52 (± 7.815)			
12 Months	5.33 (± 8.719)			
15 Months	3.28 (± 11.083)			
18 Months	7.12 (± 11.312)			
21 Months	7.18 (± 11.143)			
24 Months	6.87 (± 9.081)			
end of treatment visit	3.53 (± 9.002)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with worst post-baseline value in Functional Assessment of Cancer Therapy-G (GP5)

End point title	Percentage of participants with worst post-baseline value in Functional Assessment of Cancer Therapy-G (GP5)
End point description: The GP5 is a single question used to assess the overall bothersomeness of treatment side effects. The GP5 is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bothersomeness from treatment side effects.	
End point type	Secondary
End point timeframe: Baseline to end of treatment visit	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Participants				
Rating 0	51			
Rating 1	15			
Rating 2	10			
Rating 3	2			
Rating 4	5			
Missing	22			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall change of treatment satisfaction using Treatment Satisfaction Questionnaire (TSQM-9)

End point title	Overall change of treatment satisfaction using Treatment Satisfaction Questionnaire (TSQM-9)
End point description: The three scales of the TSQM-9 include the effectiveness scale, convenience scale, and global satisfaction scale. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction. Global Satisfaction (GS) = ({ (Item 7 + Item 8 + Item 9) -3 } / 14) * 100 Effectiveness (Eff) = ({ (Item 1 + Item 2 + Item 3) -3 } / 18) * 100 Convenience (Con) = ({ (Item 4 + Item 5 + Item 6) -3 } / 18) * 100 Total Score = Global Satisfaction + Effectiveness + Convenience	
End point type	Secondary
End point timeframe: Baseline to month 12 and 24 and end of treatment visit	

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	66			
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Global Satisfaction change from BL at 12 months	17.78 (± 29.201)			
Global Satisfaction change from BL at 24 months	17.69 (± 26.110)			
Global Satisfaction change from BL at EOT	9.96 (± 33.966)			
Effectiveness change from BL at 12 months	18.82 (± 33.809)			
Effectiveness change from BL at 24 months	17.99 (± 29.913)			
Effectiveness change from BL at EOT	14.14 (± 36.673)			
Convenience change from BL at 12 months	17.69 (± 30.758)			
Convenience change from BL at 24 months	19.05 (± 25.189)			
Convenience change from BL at EOT	15.07 (± 30.253)			
Total score change from BL at 12 months	54.29 (± 78.218)			
Total score change from BL at 24 months	54.72 (± 75.463)			
Total score change from BL at EOT	39.17 (± 86.449)			

Statistical analyses

No statistical analyses for this end point

Post-hoc: All collected deaths

End point title	All collected deaths
-----------------	----------------------

End point description:

On-treatment deaths were reported from the date of first dose of eltrombopag to 30 days after the date of the last non-zero dose of eltrombopag for patients who discontinued on or before month 12 (i.e., non-responders). For patients ongoing at month 12, the on-treatment period lasted until the cut-off date for the primary analysis (22-Oct-2021; approximately 35 months), as a patient could restart treatment at any time during study.

Post-treatment deaths were collected in the post treatment period from 31 days after last dose of study medication until the cut-off date for the primary analysis (22-Oct-2021; approximately 35 months). These are not considered Adverse Events.

End point type	Post-hoc
----------------	----------

End point timeframe:

On-treatment deaths: Up to approximately 35 months. Post-treatment deaths: Up to approximately 35 months

End point values	Eltrombopag			
Subject group type	Reporting group			
Number of subjects analysed	105			
Units: Participants				
On-treatment deaths	3			
Post-treatment deaths	1			
All deaths	4			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 35 months

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

Reporting groups

Reporting group title	All patients
-----------------------	--------------

Reporting group description:

All patients

Serious adverse events	All patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 105 (20.00%)		
number of deaths (all causes)	3		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to peritoneum			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Basal cell carcinoma			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Platelet count decreased			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			

Intentional product misuse subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Superficial vein thrombosis subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral haemorrhage subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Central nervous system haemorrhage subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Carotid artery stenosis subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhage intracranial subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Blood and lymphatic system disorders			
Thrombocytopenia			

subjects affected / exposed	3 / 105 (2.86%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Petechiae			

subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cavernous sinus thrombosis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea infectious			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonsillar abscess			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tuberculosis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	All patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	89 / 105 (84.76%)		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		

Peripheral venous disease subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hot flush subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hypertension subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 4		
Hypotension subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 3		
Extravasation blood subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	8 / 105 (7.62%) 10		
Fatigue subjects affected / exposed occurrences (all)	6 / 105 (5.71%) 7		
Discomfort subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Injection site swelling subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Malaise subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Mucosal disorder subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Mucosal haemorrhage			

<p>subjects affected / exposed occurrences (all)</p> <p>Oedema peripheral subjects affected / exposed occurrences (all)</p> <p>Pyrexia subjects affected / exposed occurrences (all)</p>	<p>2 / 105 (1.90%) 10</p> <p>4 / 105 (3.81%) 4</p> <p>5 / 105 (4.76%) 7</p>		
<p>Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)</p>	<p>2 / 105 (1.90%) 2</p>		
<p>Reproductive system and breast disorders Breast mass subjects affected / exposed occurrences (all)</p> <p>Dysmenorrhoea subjects affected / exposed occurrences (all)</p> <p>Heavy menstrual bleeding subjects affected / exposed occurrences (all)</p> <p>Intermenstrual bleeding subjects affected / exposed occurrences (all)</p> <p>Uterine polyp subjects affected / exposed occurrences (all)</p> <p>Vaginal haemorrhage subjects affected / exposed occurrences (all)</p>	<p>1 / 105 (0.95%) 1</p> <p>1 / 105 (0.95%) 1</p> <p>3 / 105 (2.86%) 4</p> <p>2 / 105 (1.90%) 2</p> <p>1 / 105 (0.95%) 1</p> <p>3 / 105 (2.86%) 4</p>		
<p>Respiratory, thoracic and mediastinal disorders Bronchitis chronic subjects affected / exposed occurrences (all)</p> <p>Cough</p>	<p>1 / 105 (0.95%) 1</p>		

subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 6		
Dysphonia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Dyspnoea subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Epistaxis subjects affected / exposed occurrences (all)	5 / 105 (4.76%) 11		
Lung infiltration subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Oropharyngeal discomfort subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Oropharyngeal pain subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 3		
Productive cough subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Rhinitis allergic subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Psychiatric disorders			
Sleep disorder subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Irritability subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Insomnia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		

Depression			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Confusional state			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Anxiety disorder			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Anxiety			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	9 / 105 (8.57%)		
occurrences (all)	10		
Aspartate aminotransferase increased			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	6		
Blood alkaline phosphatase increased			
subjects affected / exposed	7 / 105 (6.67%)		
occurrences (all)	14		
Amylase increased			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Blood bilirubin increased			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Blood creatine phosphokinase increased			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	4		
Transaminases increased			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Serum ferritin decreased			

subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Platelet count increased subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 3		
Gamma-glutamyltransferase abnormal subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Blood uric acid increased subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Blood phosphorus decreased subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 3		
Blood glucose increased subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Injury, poisoning and procedural complications			
Arthropod bite subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Contusion			

subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 6		
Head injury subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Muscle strain subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Neck injury subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Periorbital haemorrhage subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Procedural dizziness subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Procedural pain subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Wrong technique in product usage process subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Congenital, familial and genetic disorders Gilbert's syndrome subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 6		
Tachycardia subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Nervous system disorders			

Headache			
subjects affected / exposed	23 / 105 (21.90%)		
occurrences (all)	45		
Vocal cord paralysis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Presyncope			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Paraesthesia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Neuropathy peripheral			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	2		
Neuralgia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Migraine			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Hypotonia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Dysarthria			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Dizziness postural			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences (all)	5		

Cervical radiculopathy subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Cerebrovascular accident subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Autonomic nervous system imbalance subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Anosmia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	7 / 105 (6.67%) 8		
Thrombocytopenia subjects affected / exposed occurrences (all)	16 / 105 (15.24%) 31		
Haemoglobinaemia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Haemorrhagic diathesis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hyperchromasia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Iron deficiency anaemia subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 3		
Leukocytosis subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Lymphadenopathy			

subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Neutropenia subjects affected / exposed occurrences (all)	5 / 105 (4.76%) 7		
Neutrophilia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Platelet disorder subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Thrombocytosis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 2		
Bone marrow reticulin fibrosis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 3		
Eye disorders Retinal degeneration subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Cataract subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Central serous chorioretinopathy subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Eye haemorrhage			

subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Optic nerve cupping			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Periorbital oedema			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Photopsia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Retinal haemorrhage			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Visual impairment			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Scleral haemorrhage			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	7 / 105 (6.67%)		
occurrences (all)	10		
Diarrhoea			
subjects affected / exposed	10 / 105 (9.52%)		
occurrences (all)	13		
Gingival bleeding			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	6		
Nausea			
subjects affected / exposed	8 / 105 (7.62%)		
occurrences (all)	10		
Vomiting			
subjects affected / exposed	6 / 105 (5.71%)		
occurrences (all)	9		

Abdominal discomfort			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Abdominal pain upper			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Dry mouth			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Dyspepsia			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	3		
Haematochezia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Lip blister			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Mouth haemorrhage			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	3		
Odynophagia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Oral pain			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		

Stomatitis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hepatobiliary disorders			
Hepatic failure subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Cholestasis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hepatic function abnormal subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hypertransaminaemia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 5		
Skin and subcutaneous tissue disorders			
Petechiae subjects affected / exposed occurrences (all)	11 / 105 (10.48%) 18		
Acne subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Alopecia subjects affected / exposed occurrences (all)	5 / 105 (4.76%) 5		
Dermatitis allergic subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 2		
Dry skin subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Ecchymosis			

subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 3		
Eczema			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Erythema			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Night sweats			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Onychoclasia			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Pigmentation disorder			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Pruritus			
subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 5		
Purpura			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 2		
Rash			
subjects affected / exposed occurrences (all)	5 / 105 (4.76%) 7		
Rash maculo-papular			
subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Skin haemorrhage			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Skin reaction			
subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Chromaturia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Pollakiuria			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	7 / 105 (6.67%)		
occurrences (all)	10		
Joint lock			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Bone pain			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences (all)	5		
Joint swelling			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Myalgia			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Muscle spasms			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	4		
Lumbar spinal stenosis			

subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Limb discomfort subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Infections and infestations			
Gastrointestinal viral infection subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Abscess limb subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Acute sinusitis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Adenovirus infection subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Bronchitis subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
COVID-19 subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Conjunctivitis subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Coronavirus infection subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Escherichia urinary tract infection subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Eye infection viral subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		

Furuncle			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	6		
Gastroenteritis			
subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Helicobacter infection			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	4 / 105 (3.81%)		
occurrences (all)	7		
Nasopharyngitis			
subjects affected / exposed	5 / 105 (4.76%)		
occurrences (all)	6		
Onychomycosis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Oral herpes			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Papilloma viral infection			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Periodontitis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences (all)	4		
Subcutaneous abscess			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		

Suspected COVID-19 subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Tooth abscess subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Tooth infection subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 4		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 105 (2.86%) 4		
Viral infection subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 2		
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Metabolism and nutrition disorders			
Iron deficiency subjects affected / exposed occurrences (all)	4 / 105 (3.81%) 6		
Hypomagnesaemia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 105 (1.90%) 3		
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 105 (0.95%) 1		
Hypertriglyceridaemia			

subjects affected / exposed	2 / 105 (1.90%)		
occurrences (all)	2		
Hyperkalaemia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Hyperglycaemia			
subjects affected / exposed	3 / 105 (2.86%)		
occurrences (all)	4		
Hypercholesterolaemia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Dyslipidaemia			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	2		
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		
Decreased appetite			
subjects affected / exposed	1 / 105 (0.95%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 March 2019	Amendment 01: The purpose was to update the pregnancy prevention language to align with CTFG recommendations, update the biomarker sample collection schedule, add a follow-up period of 12 Months, update the DILI guidance, and align with current eltrombopag program risk language.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported